{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:22:54Z","timestamp":1780525374569,"version":"3.54.1"},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,3,4]],"date-time":"2008-03-04T00:00:00Z","timestamp":1204588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Rosacea is a common inflammatory skin disorder for which the pathogenesis is unclear. Currently, there is no cure for rosacea, and it seems that standard therapies have focused mainly on minimizing inflammation.<\/jats:p><jats:p><jats:bold>Objectives\u2002<\/jats:bold> The aim of this study is to investigate the potential efficacy, tolerability and safety profile of 1% pimecrolimus cream for the treatment of rosacea.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Twenty\u2010five patients with papulopustular rosacea were enrolled to a randomized, single\u2010blinded, placebo\u2010controlled, split\u2010face trial of pimecrolimus cream 1% consisting 4\u00a0week treatment and 2\u00a0week follow\u2010up period. The patients were instructed to apply first the \u2018left side cream\u2019 labelled placebo cream (Ultrabase cream, Intendis GmbH, Berlin, Germany) to the left hemi\u2010face then the \u2018right side cream\u2019 labelled 1% pimecrolimus cream (Elidel; Novartis Pharma, Nuremberg, Germany) to the right hemi\u2010face, twice daily. They were informed to apply a standard amount of each cream with the fingertip\u2010unit and not allowed to use any other agent concomittantly other than sunblock. Clinical evaluation and subjective severity assessment were obtained along with photographic documentation at baseline, first, second, and fourth weeks of the therapy and at the follow\u2010up visit. Rosacea severity score for each sign of erythema, papules, pustules, oedema, and telengiectesia were graded from 0 to 3. Patients were questioned for the subjective symptoms, overall improvement on appearance and side\u2010effects.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Twenty\u2010four patients completed the study with an exceptional compliance and tolerable safety profile. One patient withdrew from the study due to severe flare\u2010up reaction affecting both hemi\u2010faces. The mean baseline total rosacea severity scores were 5.06\u00a0+\u00a01.29 for both sides and reduced to 2.5<jats:italic>\u00a0\u00b1<\/jats:italic>\u00a01.06 vs. 3.25<jats:italic>\u00a0\u00b1<\/jats:italic>\u00a01.24 on pimecrolimus vs. placebo applied sides without the significance (<jats:italic>P\u00a0=<\/jats:italic>\u00a00.06). There was not any significant difference concerning each rosacea sign scores and total rosacea severity scores except for the significant improvement in erythema score and total rosacea severity score obtained on the pimecrolimus\u2010applied hemi\u2010face at 2nd week of therapy (<jats:italic>P\u00a0=<\/jats:italic>0.01 and <jats:italic>P<\/jats:italic>\u00a0=\u00a00.03, respectively). The reduction rates of the mean subjective severity scores at 4th week were 49.77% vs. 38.89% for pimecrolimus vs. placebo, respectively, without a statistical significance (<jats:italic>P\u00a0=<\/jats:italic>\u00a00.15). Subjective symptoms responded well in 54.16% of patients concerning pimecrolimus application compared with 12.50% for the placebo application. The side\u2010effects were mostly transient local irritations.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Our data implicated that pimecrolimus cream is not superior to placebo except for its efficacy on erythema. We believe that pimecrolimus cream can be a treatment option for rosacea patients with high erythema score for whom an initial accelerated improvement is needed. We believe further studies with topical pimecrolimus cream on larger study groups with different subtypes and severity of rosacea will clarify the potential effect of pimecrolimus cream for the treatment of rosacea.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2008.02589.x","type":"journal-article","created":{"date-parts":[[2008,3,4]],"date-time":"2008-03-04T22:40:48Z","timestamp":1204670448000},"page":"729-734","source":"Crossref","is-referenced-by-count":39,"title":["A randomized, single\u2010blind, placebo\u2010controlled, split\u2010face study with pimecrolimus cream 1% for papulopustular rosacea"],"prefix":"10.1111","volume":"22","author":[{"given":"AA","family":"Karabulut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B Izol","family":"Serel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HM","family":"Eksioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,3,4]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.01.048"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.03.030"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01216.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.04.084"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.03.012"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.03.033"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2006.00220.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0906-6705.2004.00269.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200708030-00003"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-9740.2005.03740.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/00015550510043975","article-title":"Pimecrolimus cream 1% is effective in a case of granulomatous rosacea","volume":"86","author":"Cunha PR","year":"2006","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-006-1179-7"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07669.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1991.tb01232.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.053"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.114739"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)02157-1"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06404.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01991.x"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.4.457"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000071800"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630601121037"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2008.02589.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2008.02589.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T05:06:36Z","timestamp":1697000796000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2008.02589.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,4]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1111\/j.1468-3083.2008.02589.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02589.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,4]]}}}